drugset / Trial / NCT05803915
Neoadjuvant Toripalimab Plus Nimotuzumab in Oral Squamous Cell Carcinoma Prior to Radical Therapy
NaSingle-groupOpen-labelTreatment
Summary
This study aims to investigate the efficacy and safety of neoadjuvant Toripalimab combined with Nimotuzumab in primary limited stage oral squamous cell carcinoma prior to radical therapy.
Timeline
- Start
- 2023-05-01
- Primary completion
- 2024-09-30
- Completion
- 2026-03-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nimotuzumab | Monoclonal antibody | 150 mg/m2 | — |
| Subject | Toripalimab | Monoclonal antibody | 240 mg | Intravenous |